Anemia, Sickle Cell Clinical Trial
Official title:
Telemedicine for Pediatric Sickle Cell Patients in Medically Underserved Areas
The purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved. Aim 1: Adapt two telemedicine models (i.e., hub-and-spoke; direct-to-consumer) for use with children with SCD using caregiver input from our preliminary K12 work. Aim 2: Demonstrate the feasibility of the telemedicine models developed in Aim 1 as the models undergo successive stakeholder refinement during use in actual clinical care. Aim 3: Evaluate the effectiveness of the refined models from Aim 2 in a pre/post study by assessing (a) process of care measures, (b) provider satisfaction, (c) caregiver/patient-centered outcomes, and (d) clinical outcomes and healthcare utilization.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | January 1, 2026 |
Est. primary completion date | January 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Caregivers must be 18 years or older, who have children between 0 to 21 years old with a diagnosis of Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic. - Adolescent patients 16 years and older are also able to participate in interviews/surveys. - The family must be willing to receive their care using the telemedicine model available to them based on the location of their primary residence. - TeleSCD model participants must live within 1 hour of the pre-identified telemedicine sites, while VirtualSCD model participants must live within the city limits of the pre-identified area. Exclusion Criteria: - If a patient receives chronic transfusion therapy, they will not be eligible to participate, as our telemedicine models will not support this. |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring adherence to appointment in sickle cell care. | Failed appointments in Electronic Medical Record - no more than one failed appointment during pilot year. | 1 year | |
Primary | Measuring adherence to lab draws in sickle cell care. | Adherence to lab draws - a minimum of one complete blood count per six months. | 6 months | |
Primary | Measuring healthcare utilization pre and post telemedicine participation. | Will determine the frequency of 1) vasoocclusive pain episode; 2) acute chest syndrome; 3) Emergency department visits; 4) hospitalizations. This data will be collected through chart abstraction from Electronic Medical Record one year prior to study entry and one year on study. | 1 year | |
Primary | Measuring collaboration of primary care provider and subspecialty care provider. | Documentation of Primary Care Provider communication of visits in the electronic medical record at least 70% of the time. | 1 year | |
Primary | Provider Feedback | Telemedicine Acceptance Questionnaire (TAQ) - will be given to all providers participating in telemedicine visits after every telemedicine visit. 0-5 Likert scale | 1 year | |
Primary | Caregiver feedback | Telemedicine satisfaction survey (TESS) - administered to caregivers following each telemedicine visit. 0-5 Likert scale | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06078696 -
Siplizumab for Sickle Cell Disease Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02561312 -
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
|
||
Completed |
NCT00890396 -
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
|
||
Completed |
NCT00059293 -
Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
|
||
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Completed |
NCT00005277 -
Cooperative Study of The Clinical Course of Sickle Cell Disease
|
N/A | |
Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A | |
Recruiting |
NCT02286154 -
Therapeutic Response Evaluation and Adherence Trial (TREAT)
|
N/A | |
Completed |
NCT02857023 -
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
|
N/A | |
Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
Terminated |
NCT00122980 -
Stroke With Transfusions Changing to Hydroxyurea
|
Phase 3 | |
Completed |
NCT00246077 -
Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport
|
N/A | |
Completed |
NCT00094887 -
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
|
Phase 2 | |
Completed |
NCT00035763 -
Pain in Sickle Cell Epidemiologic Study
|
N/A | |
Terminated |
NCT04091737 -
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT00005300 -
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
|
N/A | |
Recruiting |
NCT04351698 -
SMILES: Study of Montelukast in Sickle Cell Disease
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06290401 -
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
|
Phase 2 |